Hengrui Pharma
Hengrui Medicine Co., Ltd., commonly known as Hengrui Pharma, is a leading biopharmaceutical company headquartered in China (CN). Founded in 1993, Hengrui has established a strong presence in the global pharmaceutical industry, focusing on innovative drug development, manufacturing, and marketing. The company operates extensively across Asia, Europe, and North America, positioning itself as a key player in oncology, anaesthesia, and imaging agents. Hengrui Pharma is renowned for its commitment to research and development, with a diverse portfolio that includes targeted therapies and biologics. Its unique approach to drug formulation and delivery has garnered recognition, contributing to its market leadership. With numerous accolades and a robust pipeline of products, Hengrui continues to advance healthcare solutions, making significant strides in improving patient outcomes worldwide.
DitchCarbon Score
How does Hengrui Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hengrui Pharma's score of 33 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hengrui Pharma's reported carbon emissions
In 2024, Hengrui Pharma reported total carbon emissions of approximately 257,897,240 kg CO2e, comprising about 8,516,600 kg CO2e from Scope 1 and about 249,380,640 kg CO2e from Scope 2 emissions. This marks a significant increase from 2023, where total emissions were about 208,280,090 kg CO2e, with Scope 1 emissions at approximately 4,898,000 kg CO2e and Scope 2 emissions at about 203,382,080 kg CO2e. Hengrui Pharma has set ambitious climate commitments, aiming for carbon neutrality by 2050. The company has established near-term reduction targets for both Scope 1 and Scope 2 emissions, with a focus on reducing carbon emissions during operations from 2023 to 2025. Additionally, a long-term roadmap was released, committing to peak carbon emissions by 2029. The emissions data is sourced from Jiangsu Hengrui Medicine Co., Ltd., and no Scope 3 emissions data has been disclosed. Hengrui Pharma's initiatives reflect a growing commitment to sustainability within the pharmaceutical industry, aligning with global climate action goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 8,837,680 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 235,222,570 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hengrui Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
